[Rapporto di ricerca] Si prevede che le dimensioni del mercato dei teranostici radiofarmaceutici cresceranno da 1.814,58 milioni di dollari nel 2022 a 3.441,97 milioni di dollari entro il 2028; Si stima registrerà un CAGR dell'11,3% tra il 2022 e il 2028.
Il mercato della teranostica radiofarmaceutica è segmentato in base al tipo di prodotto, radioisotopo, fonte, applicazione, indicazione, utente finale e geografia. Il rapporto offre approfondimenti e analisi approfondite del mercato, sottolineando parametri quali dinamiche, tendenze e opportunità prevalenti nel mercato Teranostica radiofarmaceutica. Fornisce inoltre l'analisi del panorama competitivo dei principali attori del mercato globale della terapia radiofarmaceutica.
Approfondimenti di mercato
La crescente applicazione nel trattamento dei disturbi cardiovascolari guida la crescita del mercato globale della terapia radiofarmaceutica
Le malattie cardiovascolari (CVD) sono tra le malattie croniche più diffuse del 21° secolo, con un elevato tasso di mortalità. A causa del loro stile di vita sedentario, le malattie cardiovascolari sono la principale causa di mortalità e morbilità nei paesi sviluppati. Inoltre, l’obesità, il diabete e le malattie correlate sono associati a malattie cardiovascolari e stanno diventando comorbidi. Inoltre, una complicanza come l'ostruzione dell'arteria coronaria è una delle principali cause di morte negli adulti, causando la formazione di trombi nell'intima della parete arteriosa, principalmente nell'arteria carotide. Secondo i dati del Centro nazionale per le biotecnologie, nel 2015 nel mondo sono morte circa 17,7 milioni di persone a causa di malattie cardiovascolari. A questo proposito, si stima che la mortalità per malattie cardiovascolari potrebbe aumentare fino a 22 milioni entro il 2030. Le applicazioni terapeutiche nelle malattie cardiovascolari includono la nanomedicina nell'angina pectoris, nella miocardite, nell'infarto del miocardio, nella malattia del pericardio, nella trombosi, nell'aterosclerosi, nell'iperlipidemia, nell'ipertensione, nella malattia arteriosa polmonare ipertensione e ictus. Le nanomedicine teranostiche possono prolungare la circolazione sistemica, eludere i sistemi di difesa dell'ospite e fornire agenti teranostici al sito bersaglio per l'imaging e la terapia a livello cellulare e molecolare.
Approfondimenti strategici
Secondo il Rapporto 2022 dei Centri per il controllo e la prevenzione delle malattie (CDC), le malattie cardiache sono una delle principali cause di morte tra uomini e donne negli Stati Uniti. Le malattie cardiache sono state la causa di circa 697.000 decessi, ovvero 1 decesso su 5, negli Stati Uniti nel 2020. Un rapporto del National Institute of Health (NIH) afferma che le nanoparticelle teranostiche hanno guadagnato un'attenzione significativa in campo medico, poiché le tecniche aiutano a superare complessità e complicanze fisiopatologiche associate alle malattie cardiovascolari. L’imaging cardiovascolare dei pazienti affetti da aterosclerosi fornisce prove fisiopatologiche che possono aiutare a trattare le malattie cardiovascolari. Inoltre, le nanoparticelle teranostiche possono essere combinate con una serie di tecniche di imaging, come la risonanza magnetica (MRI), la tomografia a emissione di positroni (PET) e la tomografia computerizzata (CT). Finora sono stati condotti vari studi di ricerca clinica nei laboratori clinici. È stato costruito un complesso terapeutico tre in uno, combinando una sonda fotoacustica polimerica con nanoparticelle-PLCDP@PMH. Le valutazioni cliniche in vivo rivelano che PLCDP@PMH offre vantaggi redditizi per l'approccio teranostico al rilevamento dell'aterosclerosi in stadio iniziale nei pazienti.
Approfondimenti basati sul tipo di prodotto
In base al tipo di prodotto , il mercato della teranostica radiofarmaceutica è segmentato in traccianti per tomografia a emissione di positroni (PET), emettitori beta ed emettitori alfa. Nel 2022, il segmento dei traccianti per tomografia a emissione di positroni (PET) deteneva la quota maggiore del mercato globale della teranostica radiofarmaceutica e si prevede che registrerà il CAGR più elevato durante il periodo di previsione.
Mercato della teranostica radiofarmaceutica, per tipo di prodotto: 2022-2028
Approfondimenti basati sui radioisotopi
Sulla base del radioisotopo, il mercato della teranostica radiofarmaceutica è suddiviso in lutezio (Lu) 177, gallio-68, iodio-131, iodio-123, Tecnezio-99, Ittrio-90 (Y-90), Rame (Cu) 64, 18F, Rame (Cu) 67 e altri. Nel 2022, il segmento Lutezio (Lu) 177 deteneva la quota di mercato maggiore del mercato globale della teranostica radiofarmaceutica e si prevede che registrerà il CAGR più elevato durante il periodo di previsione.
Approfondimenti basati sulla fonte
< p> In base alla fonte, il mercato della teranostica radiofarmaceutica è suddiviso in ciclotroni e reattori nucleari. Il segmento dei ciclotroni deteneva una quota maggiore del mercato nel 2022 e si prevede che registrerà un CAGR più elevato durante il periodo di previsione.Approfondimenti basati sull'applicazione
Basati sull'applicazione, il mercato dei radiofarmaci teranostici è diviso in terapeutico mirato (Rx) e diagnostico complementare (CDx). Nel 2022, il segmento terapeutico mirato (Rx) deteneva una quota maggiore del mercato e si prevede che registrerà un CAGR più elevato durante il periodo di previsione.
Approfondimenti basati sull'indicazione
Sulla base delle indicazioni, il mercato dei teranostici radiofarmaceutici è segmentato in oncologia, neurologia, cardiologia e altri. Il segmento oncologico ha detenuto la quota maggiore del mercato nel 2022 e si prevede che registrerà il CAGR più elevato durante il periodo di previsione.
Approfondimenti basati sull'utente finale
Basati sull'utente finale , il mercato dei radiofarmaci teranostici è segmentato in ospedali, centri di imaging diagnostico, istituti accademici e di ricerca e altri. Il segmento degli ospedali deteneva la quota di mercato maggiore nel 2022. Tuttavia, si prevede che il segmento degli istituti accademici e di ricerca registrerà il CAGR più elevato durante il periodo di previsione. Gli ospedali utilizzano sistemi tecnologicamente avanzati per trattare aneurismi cardiaci, aneurismi neurologici, tumori oncologici e altre condizioni simili. La crescente prevalenza di varie malattie e un numero crescente di ospedali contribuiscono alla crescita del mercato del segmento ospedaliero.
Gli operatori del mercato dei radiofarmaci teranostici adottano strategie organiche, come il lancio e l'espansione del prodotto, per espandere la propria presenza e portafoglio prodotti e soddisfare le crescenti richieste. Le strategie di crescita inorganica testimoniate nel mercato sono partnership e collaborazioni. Queste strategie di crescita hanno consentito agli operatori del mercato di espandere le proprie attività e migliorare la propria presenza geografica. Inoltre, acquisizioni, partnership e altre strategie di crescita li aiutano a rafforzare la propria base di clienti.
- Nell'ottobre 2022, Telix ha ricevuto l'approvazione di Health Canada per il suo Illuccix, un kit per la preparazione dell'iniezione di gallio (68Ga) gozetotide. Il prodotto può essere utilizzato nella stadiazione e nella ristadiazione del cancro alla prostata a rischio intermedio e alto e nella localizzazione del tessuto tumorale nel cancro alla prostata ricorrente. Illuccix è stato il primo agente di imaging PET PSMA a ottenere l'approvazione normativa in Canada. Health Canada è stato il terzo ente normativo a livello mondiale ad approvare Illuccix, disponibile in commercio in Australia e negli Stati Uniti.
- Nel dicembre 2021, GE Healthcare e Minerva Imaging hanno stretto una partnership strategica per accelerare il lancio commerciale di farmaci mirati. ;terapie con radionuclidi (teranostici). La terapia con radionuclidi è una forma di medicina di precisione in cui una sostanza radioattiva viene somministrata attraverso il flusso sanguigno per colpire le cellule tumorali e irradiarle in modo specifico. Ciò aiuta a ridurre i potenziali effetti collaterali rispetto alle tradizionali terapie antitumorali.
Profili aziendali - Mercato dei prodotti teranostici radiofarmaceutici
- Bayer AG
- GE HealthCare Technologies Inc
- Curium
- Lantheus Medical Imaging, Inc.
- Telix Pharmaceuticals Ltd.
- Cardinal Health Inc
- Advanced Accelerator Applications SA
- Jubilant Radiopharma
- Theragnostics
- NuView Life Sciences
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Radiopharmaceuticals are radioisotopes that are bound to biological molecules that target specific tissues, organs, or cells within the human body. Radioisotopes emitting gamma rays are useful for diagnostic imaging where the radiation escapes the body. Nuclear medicine imaging generally utilizes radioactive isotopes attached to specific molecules to examine biological processes, such as disease pathophysiology. Every radiopharmaceutical is designed to travel to a specific location in the body, and as soon as it reaches the site, it releases radioactive substances that kill the tumor cells. Radiopharmaceuticals can target various malignancies such as prostate cancer, heart disease, thyroid cancer, and others. These drugs can also be used as both therapies and diagnostics, known as 'theranostics’. In theranostics, radiopharmaceuticals are used for therapeutic and diagnostic purposes by targeting one specific tumor receptor.
Key factors that are driving the growth of this market are rising incidence of cancer and the growing application in the treatment of cardiovascular disorders are expected to boost the market growth for the radiopharmaceutical theranostics over the years.
The CAGR value of the biopharmaceuticals market during the forecasted period of 2022-2028 is 11.3%.
The positron emission tomography (PET) tracers segment held the largest share of the market in the global radiopharmaceutical theranostics market and held the largest market share of 44.76% in 2022.
The Lutetium (Lu) 177 segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 24.34% in 2022.
The cyclotrons segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 60.42% in 2022.
Answer: - The targeted therapeutic [Rx] segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 63.28% in 2022.
The oncology segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 62.18% in 2022.
The hospitals segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 36.28% in 2022.
The radiopharmaceutical theranostics market majorly consists of the players such Bayer AG, GE HealthCare Technologies Inc, Curium, Lantheus Medical Imaging, Inc.; Telix Pharmaceuticals Ltd.; Cardinal Health Inc, Advanced Accelerator Applications S.A.; Jubilant Radiopharma, Theragnostics, and NuView Life Sciences amongst others.
The List of Companies - Radiopharmaceutical Theranostics Market
- Bayer AG
- GE HealthCare Technologies Inc
- Curium
- Lantheus Medical Imaging, Inc.
- Telix Pharmaceuticals Ltd.
- Cardinal Health Inc
- Advanced Accelerator Applications S.A.
- Jubilant Radiopharma
- Theragnostics
- NuView Life Sciences
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2023
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2023
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2023
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2023
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2023
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Mar 2023
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Mar 2023
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)